Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Nanotoday who wrote (4819)	6/1/2015 8:51:50 PM
From: HardToFind	Read Replies (1) \| Respond to of 12871

My suspicion is that Kard and BASi have provided FORMAL testing services (i.e., test results), whereas institutions like UC Berkeley have probably collaborated in development and cross-licensed intellectual property to NNVC during the development phase. I'm guessing that you don't want to mix the two relationships. You DON'T want your FORMAL test contractors to be financially leveraged to the positive or negative results of their testing, only rewarded for the accuracy, reliability and formal compliance of their testing and test procedures. The FDA sees these results and wants them to be objective. On the other hand, you DO want your developmental collaborators and intellectual property providers to be financially leveraged to the successful results of their developments and discoveries. You want them to be very motivated to provide their best innovation and ideas. The FDA doesn't really care very much about the origin of your ideas and largely doesn't consider these results in the drug approval process.